Sarah Berman

University of Pittsburgh — United States

Medicine · Health Sciences

42h-index7.9kcitations169works7.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dementia and Cognitive Impairment Research(81), Alzheimer's disease research and treatments(79), Functional Brain Connectivity Studies(24), Parkinson's Disease Mechanisms and Treatments(23), Mitochondrial Function and Pathology(18)

Publications158 total

Cortical asymmetry in autosomal dominant Alzheimer’s disease progression
Brain Communications·2025Open Access
Leveraging electronic health records to examine outcome disparities in people with Alzheimer's Disease
Alzheimer s & Dementia·2025Open Access
Pittsburgh Brain Health Initiative (BHI): protocol and methods for an observational study of cognitive function in former professional football players and controls
BMJ Open·2025Open Access
Diagnostic Performance of Plasma Phospho‐tau217 for Alzheimer's Disease in a Large Memory Clinic Cohort
Alzheimer s & Dementia·2025Open Access
High <i>p</i> ‐Tau217 Levels Nullify Age‐related Cognitive Protection in Younger Older Adults
Alzheimer s & Dementia·2025Open Access
CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies
Neurology·2025· 2 cited
Performance of 123I‐ioflupane SPECT striatal binding in dementia with Lewy bodies
UNC Libraries·2025Open Access
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
Alzheimer s & Dementia·2025· 2 citedOpen Access
Performance of <sup>123</sup> I‐ioflupane SPECT striatal binding in dementia with Lewy bodies
Alzheimer s & Dementia·2025Open Access
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
Alzheimer s & Dementia·2025· 2 citedOpen Access
Comparison of visual and analytic methods of Alzheimer's disease pathologic staging
Alzheimer s & Dementia·2025Open Access
Lessons from the Tim Greenamyre model
Neurobiology of Disease·2025Open Access
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease
Acta Neuropathologica·2025· 3 citedOpen Access
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
Alzheimer s & Dementia·2025· 4 citedOpen Access
Leveraging electronic health records to examine differential clinical outcomes in people with Alzheimer’s Disease
2025Open Access
CSF aSyn-SAA and Alzheimer’s Disease Biomarkers: Presentation and Progression in the Dementia with Lewy Bodies Consortium (P7-3.011)
Neurology·2025· 2 cited
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
The Lancet Neurology·2025· 27 cited
Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia
Nature Medicine·2025· 16 cited
The landscape of autosomal-dominant Alzheimer’s disease: global distribution and age of onset
Brain·2025· 7 citedOpen Access
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Alzheimer s Research & Therapy·2025· 10 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Randall J. Bateman(28), Tammie L.S. Benzinger(26), John C. Morris(25), Eric McDade(25), Brian A. Gordon(24), Jasmeer P. Chhatwal(24), Stephen Salloway(21), Johannes Levin(21), Jason Hassenstab(20), Chengjie Xiong(20), Peter R. Schofield(20), Nick C. Fox(20), Anne M. Fagan(19), Carlos Cruchaga(19), Alison Goate(18), Ricardo Allegri(18), Colin L. Masters(18), Mathias Jucker(18), Richard J. Perrin(17), Celeste M. Karch(16)